SCHEDULE 13G

CUSIP No.

61023L207

1

Names of Reporting Persons

AstraZeneca PLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 522,667.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 522,667.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

522,667.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

11

Percent of class represented by amount in row (9)

7.8 %

12

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person: Note to Rows 5, 7 and 9: Represents shares directly held by Alexion Pharmaceuticals, Inc., a wholly-owned subsidiary of AstraZeneca PLC. AstraZeneca PLC and Alexion Pharmaceuticals, Inc. may each be deemed to have sole voting and dispositive power over the shares. Note to Row 11: Based upon 6,682,584 shares of Common Stock of the Issuer outstanding as of October 31, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q ("Form 10-Q") filed with the Securities and Exchange Commission (the "SEC") on November 13, 2025.

SCHEDULE 13G

CUSIP No.

61023L207

1

Names of Reporting Persons

Alexion Pharmaceuticals, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 522,667.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 522,667.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

522,667.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

11

Percent of class represented by amount in row (9)

7.8 %

12

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person: Note to Rows 5, 7 and 9: Represents shares directly held by Alexion Pharmaceuticals, Inc., a wholly-owned subsidiary of AstraZeneca PLC. AstraZeneca PLC and Alexion Pharmaceuticals, Inc. may each be deemed to have sole voting and dispositive power over the shares. Note to Row 11: Based upon 6,682,584 shares of Common Stock of the Issuer outstanding as of October 31, 2025, as reported in the Issuer's Form 10-Q filed with the SEC on November 13, 2025.

SCHEDULE 13G

Item 1.

(a)

Name of issuer:

Monopar Therapeutics Inc.

(b)

Address of issuer's principal executive offices:

1000 Skokie Blvd., Suite 350 Wilmette, IL, 60091

Item 2.

(a)

Name of person filing:

See response to Item 2(c).

(b)

Address or principal business office or, if none, residence:

See response to Item 2(c).

(c)

Citizenship:

This statement is filed on behalf of: AstraZeneca PLC 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA Citizenship: United Kingdom Alexion Pharmaceuticals, Inc. 121 Seaport Boulevard Boston, Massachusetts 02210 Citizenship: United States of America

(d)

Title of class of securities:

Common Stock, $0.001 par value per share

(e)

CUSIP No.:

61023L207

Item 3.

If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b)

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d)

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)

An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f)

An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g)

A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h)

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)

A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:

(k)

Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4.

Ownership

(a)

Amount beneficially owned:

522,667 shares

(b)

Percent of class:

7.8%. Based upon 6,682,584 shares of Common Stock of the Issuer outstanding as of October 31, 2025, as reported in the Issuer's Form 10-Q filed with the SEC on November 13, 2025.

(c)

Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

AstraZeneca PLC: 522,667 shares Alexion Pharmaceuticals, Inc.: 522,667 shares

(ii) Shared power to vote or to direct the vote:

AstraZeneca PLC: 0 shares Alexion Pharmaceuticals, Inc.: 0 shares

(iii) Sole power to dispose or to direct the disposition of:

AstraZeneca PLC: 522,667 shares Alexion Pharmaceuticals, Inc.: 522,667 shares

(iv) Shared power to dispose or to direct the disposition of:

AstraZeneca PLC: 0 shares Alexion Pharmaceuticals, Inc.: 0 shares

Item 5.

Ownership of 5 Percent or Less of a Class.

Not Applicable

Item 6.

Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8.

Identification and Classification of Members of the Group.

Not Applicable

Item 9.

Notice of Dissolution of Group.

Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

AstraZeneca PLC

Signature:	/s/ Matthew Bowden
Name/Title:	Matthew Bowden / Company Secretary
Date:	02/06/2026

Alexion Pharmaceuticals, Inc.

Signature:	/s/ Todd Spalding
Name/Title:	Todd Spalding / Secretary
Date:	02/06/2026

Amendment: SEC Form SCHEDULE 13G/A filed by Monopar Therapeutics Inc.